AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06416462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial photodynamic therapy
Description: When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.
Study NCT06416462 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: antimicrobial photodynamic therapy
Description: When starting the research, all wounds, regardless of the study group, will be cleaned with 0.9% saline solution (SF0.9%), using a 40x12 needle and a 500ml bottle of SF0.9%, in order to maintain pressure. for equal cleaning of all wounds and a hydrofiber plate with silver was used as standard coverage. Experimental group (n=45): When starting the intervention, all services in both groups will follow the cleaning standard described previously. In the aPDT group, 1% methylene blue will be used as a photosensitizer applied with the aid of a syringe (with a pre-irradiation time of 5 minutes), 6 J of laser will be applied.
Study NCT05219110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of 200% maintenance fluids as balanced crystalloid IV solution
Description: Infusion of 200% of maintenance fluids x 24 hours provided, ideally, as a balanced crystalloid (PlasmaLyteTM, Ringer's Lactate) IV solution. Electrolytes and dextrose may be administered as required and desired by the clinical care team; customized solutions are permitted if so desired. Intravenous fluid solutions containing \< 130 mEq/L sodium may increase risk for hyponatremia and may be less effective in achieving intravascular volume expansion and should be avoided.
Study NCT05219110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Description: Administration of less than or equal to 110% of maintenance fluids as oral or balanced crystalloid IV solution.
Study NCT05119283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scraping and straightening of the crown and root and rinsing with mouthwashes
Description: Patients will answer a questionnaire about their socioeconomic conditions, and soon after undergoing the examination for bleeding, probing, clinical attachment level, probing depth and plaque index for initial clinical evaluation. Basic periodontal treatment will be carried out with the same operator (blind to the treatments performed), with complete removal of plaque and calculi, prophylaxis with pumice and prophylactic paste and oral hygiene instructions. After basic periodontal treatment, patients will be randomly divided based on a draw with closed, opaque and non-translucent envelopes, into 3 groups according to the supporting treatments: G1 - patients who will receive mouthwashes with saline solution; G2 - patients who will be rinsed with 0.12% chlorhexidine and G3 - patients who will be treated with PHTALOX®.
Study NCT06400823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR+TENS
Description: During the invention, patients will be in VR scenarios and play task-oriented games, interacting with elements that appear in the virtual world, to improve mobility and functional independence of the upper limbs.~The task-oriented games will target different components depending on the disability of the patient.
Study NCT06400823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Patients will perform conventional upper-limb stroke rehabilitation. The movement performed will be comparable with the movement performed in the VR+TENS group
Study NCT06408103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component, transdisciplinary and multifocal intervention for the cognition
Description: Multi-component intervention (12 weeks, twice/week, with professional support at home)~Physical activity for the patient: dual training, strength, balance, with intensity increase monthly, plus moderate walking of 30 minutes/day, 5 days per week.~Nutritional advice for the patient: Month 1- reduction of added sugars and processed carbohydrates. Month 2- increase consumption of healthy fats and reduction of saturated fats; Month 3- increase in consumption of fruits and vegetables, and a monthly group practical workshop.~Cognitive training for the patient: activities focused on orientation, attention and concentration, working memory, mathematical reasoning, language, visual construction, executive functions, and reminiscence therapy.~Accompaniment for the family member: Activities aimed at care and self-care, understanding cognitive deterioration and its progression, support for patient adherence to the intervention, and activities in groups once a week.
Study NCT05807477 — intervention group
Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-15)
Study NCT05362318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch and lozenges
Description: Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke >10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
Study NCT05362318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch and lozenges
Description: Participants will receive nicotine patch and lozenges. The regimen will be based on the participant's self-reported smoking rate. At the time of enrollment, a research staff member will determine the proper dose. Participants who smoke >10 cigarettes/day will receive 8 weeks of 21 mg. patches, 2 weeks of 14 mg. patches, 2 weeks of 7 mg. patches, and 12 weeks of 2 mg. lozenges. Those who smoke \<10 cigarettes/day will receive 8 weeks of 14 mg. patches, 4 weeks of 7 mg patches, and 12 weeks of 2 mg. lozenges
Study NCT05362318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling sessions
Description: Participants will be offered 6 Motivation and Problem Solving (MAPS)-based counseling sessions by phone over a 6-month period.
Study NCT05362318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to a web-based video
Description: Participants will be given web-based access to the relapse prevention video Surviving Smokefree.
Study NCT05362318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Florida Tobacco Quitline
Description: Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
Study NCT05362318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Florida Tobacco Quitline
Description: Participants will receive an offer of enrollment to the Florida Tobacco Quitline which enables participant to speak with a Quit Coach who will assess nicotine addiction and help create a quit plan.
Study NCT06170918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: remimazolam is given intravenously
Study NCT05426278 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bair hugger and Forces air warmer
Description: The EQUATOR™ (EQ-5000) air-warmer is a convective warmer, with the average and maximum Contact Surface Temperatures of 39℃ \& 44℃ Respectively. Temperature on this device can be set at 36℃ , 40℃ , 44℃. The 3M™ Bair Hugger ™ (SW-2003) upper body blanket is used to warm the body from head till the xiphisternum
Study NCT05219058 — intervention group
Intervention type: PROCEDURE
Intervention: Biological mesh reconstruction
Description: Patients receiving biological mesh of any kind or position as part of their reconstruction during surgery.
Study NCT05219058 — intervention group
Intervention type: PROCEDURE
Intervention: Myocutaneous flap reconstruction
Description: Patients receiving a myocutaneous flap of any kind as part of their reconstruction during surgery.
Study NCT05219058 — intervention group
Intervention type: PROCEDURE
Intervention: Primary closure reconstruction
Description: Patients receiving primary closure only using any suture material or technique as part of their reconstruction during surgery.
Study NCT06490042 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A questionnaire about helmet use and attitude towards helmet use.
Study NCT05940584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tele-Reha provided with EvoPads
Description: Exercises and cognitive training provided on an EvoPad
Study NCT05940584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based exercises with option to do tele-reha afterwards
Description: Similar exercises and cognitive training as Group 1 provided on paper. Patients receive the Tele-Reha afterwards
Study NCT05940584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only paper-based exercises
Description: Same exercises and cognitive training as Group 2 provided on paper only.
Study NCT04943965 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound imaging
Description: The intervention is non-invasive, chest wall, echocardiographic image acquisition in the cardiac operating room prior to a scheduled cardiac surgery. Echocardiographic images will be taken at three, key, timepoints in the operating room prior to cardiac surgery:~1. Pre-induction.~2. Post-induction / Pre-PAC~3. Post-induction / Post-PAC
Study NCT04964453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
Study NCT04964453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121
Description: Healthy subjects were given a single dose of BI 474121 as a uncoated tablet(s) taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
Study NCT06095466 — intervention group
Intervention type: DEVICE
Intervention: Echocardiographic assessment
Description: M mode, cross sectional and pulsed wave Doppler Echocardiographic examinations will be performed using a with a 2.5 MHz wide angle phased array transducer. Patients will be laid in left lateral position and examined in standard parasternal long and short axis and apical views. Short axis recordings will be performed at the level of the papillary muscles. M mode tracings will be recorded at the level of the papillary muscles and the aortic valves, with 2 -D guidance. LV wall thickness and cavity diameters will be measured by M mode, through the largest diameter of the ventricle, if possible, both in diastole and systole. Using the cross-sectional images as a guide, the M mode tracing of the left ventricle will obtained to calculate measurements according to the recommendations of American Society of Echocardiography.
Study NCT06095466 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Immunohistochemistry
Description: In patients who do not survive, we will take a trucut core biopsy from the ventricular myocardium, using ultrasound guidance. Cardiac tissue slices preserve the heterogeneous structure and multicellularity of the myocardium and allow its functional characterization. However, in this protocol, only those patients who consent to autopsy or those who consent to most mortem biopsy will be sampled for cardiac histology in CCM. Thus samples for histology and immunohistopathology will be available in only a few patients.~For the immunohistochemistry study, the sections will be collected on the poly-L-lysine covered slides and dried in a thermostat, at 37°C, for 24 hours, for increasing the adherence of the biological material to the histological slide.
Study NCT04138875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
Study NCT04138875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
Study NCT04138875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
Study NCT05862064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab
Description: Conventional chemotherapy in combination with carrelizumab
Study NCT05862064 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: epirubicin,cyclophosphamide,paclitaxel
Description: Conventional chemotherapy
Study NCT06227507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-package label
Description: Participants will identify the healthfulness of three packaged foods, each displayed with front-of-package labels as specified by their assigned group.
Study NCT06421376 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy ±immunotherapy
Description: Chemoradiotherapy ± immunotherapy：~* PTV: 50-50.4Gy/1.8-2Gy/25-28fractions ②nab-paclitaxel 100mg+cisplatin 25mg/ m2, d1, every 7 days for 3-5 weeks ③Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
Study NCT06421376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Surgery was evaluated after concurrent chemoradiotherapy according to patients willing and the surgeons' assessment. If patients were accessed with unresectable disease after radiotherapy or refused to receive surgery, Cardonilizumab would be administered for 2 years or until disease progression.
Study NCT05835180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640 - 50 mg
Description: TVB-2640 -50 mg administered orally once daily
Study NCT04820413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Description: FMT by daily enema with donor faeces
Study NCT06335316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT06335316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: the patients were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g)
Study NCT06335316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
Study NCT06335316 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comprehensive therapy
Description: All the participants are provided with the comprehensive rehabilitation (routine rehabilitation and swallowing function training). The routine rehabilitation included intervention for risk factors (blood pressure, blood lipids, blood glucose, smoking and alcohol restriction, exercise, etc.).
Study NCT06335316 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck. Only normal saline was used
Study NCT05760768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized exercise guidance
Description: Participants accept individualized exercise guidance. They are also managed continuously through WeChat group chat during prenatal clinical interval.
Study NCT04993443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQ036
Description: For Each part of the study, a staggered dosing schedule may be used for the first dose level, in each cohort including 2 sentinel subjects (1 active and 1 placebo) initiating dosing first and the remaining 6 subjects for Part A-C and 8 subjects for Part D initiating dosing no sooner than the next day. Each study part (A, B, C, and D) will be completed sequentially, but with partial overlapping. Part B and C may only be initiated after review of the safety, tolerability, and PK data following dosing of the SAD Cohort 3 or 4.~Part D may be initiated when safety tolerability and PK data are known and deemed acceptable by the SRC for multiple doses in Part B, at least at the same concentration to be administered in Part D.
Study NCT04993443 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo for LQ036: Matching Placebo
Study NCT04579159 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Preventicus heartbeat app in combination with wearables
Description: CE certified devices
Study NCT06076174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-week home-based exercise programme
Description: All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
Study NCT06076174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week home-based exercise programme
Description: All participants will have an in-person session with the physiotherapist for exercise demonstration before beginning the programme. They will carry out the exercises independently at home over a period of six weeks, thrice a week, giving a total of 18 sessions, each lasting 30 minutes.
Study NCT05656729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DefensePlus
Description: Multistrain probiotic:L. plantarum PBS077, L. acidophilus PBS066, B. lactis BL050, Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
Study NCT05656729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrins, Vitamin B12, Vitamin, B6 Folic acid, Magnesium, silicon dioxide
Study NCT05146193 — intervention group
Intervention type: OTHER
Intervention: Nude back photo
Description: Nude back photo at baseline and at follow-ups for each patient and visual severity and curve type classifications
Study NCT06481215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-068
Description: The investigational product GNR-068 was administered as a subcutaneous injection at a single dose of 45 mg.
Study NCT06481215 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara®
Description: The reference product Stelara® was administered as a subcutaneous injection at a single dose of 45 mg.
Study NCT05216302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Nordic Walking Exercise Program
Description: An exercise intervention based on nordic walking and health education of one hour and 15 minutes per session. Each session includes 10 min of health education followed by 15 minutes of warm-up exercises, 30 minutes of nordic walking and finally 15 min to cool-down. The intervention is meant to last during two months (last round of chemotherapy and one month pre-surgery), twice weekly for approximately a total of 16 sessions.
Study NCT04808141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital program
Description: Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health. These patients will be referred to SWORD Health by the investigator who identified the candidate. SWORD Health will then assign a physical therapist to each patient. The physical therapist will contact the patient for onboarding and will manage the case.
Study NCT04808141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face PT sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program will follow the protocol outlined in Annex 3, which can however be adapted by the physical therapist to the specific needs of the participant. Participants in this group will be considered as dropouts if they: a) choose to abandon the study; b) miss four consecutive scheduled PT sessions.